Creating a healthier, better connected Gippsland.

COVID-19 Antiviral Information

Information for health professionals

Most cases of COVID-19 are mild and can be managed at home. Some people who are at higher risk may need specific antiviral treatments prescribed by their healthcare provider. See information below about antiviral treatments.

Information and resources

There is a range of information and resources available to support healthcare providers and healthcare professionals.

Click on the toggles below to find out more about what is on offer to support you.

Gippsland HealthPathways can help you.  Click here to access the pathways.

Victorian guidance

To support prescribing, the Victorian Department of Health continues to provide PBS prescribers access to the Victorian COVID-19 therapies PBS prescriber helpline and clinical decision-making guidance (which includes a Paxlovid prescribing flowchart).

More information on these here:

Updated Paxlovid prescribing guide flowchart

The National COVID-19 Clinical Evidence Taskforce has collaborated with the department to produce and publish a PaxlovidTM prescribing guide. Modelled on the department’s guide, this document acts as a key reference for clinicians when considering the PaxlovidTM for early treatment of COVID-19 in eligible patients. PaxlovidTM is the preferred treatment for eligible patients, where it is determined to be suitable, as it has higher efficacy that LagevrioTM in reducing hospitalisations and deaths in high risk patients.

The PaxlovidTM prescribing guide is available at and will be linked from the department’s medicines website. For further prescribing resources see:

National COVID-19 Evidence Taskforce

The National COVID-19 Evidence Taskforce supports Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines.

Information includes a flow chart for drug treatments for adults with COVID-19.

Find out more at

Revised factsheet

Please find attached the revised fact sheet on EvusheldTM for clinicians. This updated document is a live document and will be available on the Department of Health website.

This EvusheldTM fact sheet for clinicians document is updated and includes: 

  • A recommendation to maintain current dosing
  • A recommendation for COVID-19 vaccination timing following administration of EvusheldTM
  • Advice on early therapies following COVID-19 infection and EvusheldTM administration
  • Rollout of the GP and non-GP specialist community prescriber pathway 

As the COVID-19 pandemic evolves, the role of GPs is becoming even more important for managing at-risk patients
in the community.

An estimated 35,000 DVA patients are considered at risk of progressing to severe illness and needing hospitalisation if they
develop COVID-19 infection. See the fact sheets below.

COVID-19 Antiviral Medicines_GP Factsheet

COVID-19 Antiviral Medicines_GP Factsheet

Interactive locator map

Gippsland PHN has developed a map of pharmacies that stock COVID-19 antivirals. This information lists Community Pharmacies located within Gippsland that stock Lagevrio and Paxlovid.

If you are a pharmacy that is not included in this map, please email with your information.

This information is indicative only.

doctors in secondary schools program